| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2983 | 2019 |
| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2399 | 2019 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1598 | 2019 |
| Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ... Journal of Clinical Oncology 38 (35), 4138-4148, 2020 | 764 | 2020 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 457 | 2021 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 405 | 2020 |
| Abiraterone and olaparib for metastatic castration-resistant prostate cancer NW Clarke, AJ Armstrong, A Thiery-Vuillemin, M Oya, N Shore, E Loredo, ... NEJM evidence 1 (9), EVIDoa2200043, 2022 | 237 | 2022 |
| Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial MG Fakih, S Kopetz, Y Kuboki, TW Kim, PN Munster, JC Krauss, ... The Lancet Oncology 23 (1), 115-124, 2022 | 201 | 2022 |
| PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant … F Saad, AJ Armstrong, A Thiery-Vuillemin, M Oya, E Loredo, G Procopio, ... Journal of Clinical Oncology 40 (6_suppl), 11-11, 2022 | 84 | 2022 |
| Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651 RI Haddad, K Harrington, M Tahara, RL Ferris, M Gillison, J Fayette, ... Journal of Clinical Oncology 41 (12), 2166-2180, 2023 | 71 | 2023 |
| A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial G de Castro Junior, JG Segalla, SJ de Azevedo, CJ Andrade, D Grabarz, ... European journal of cancer 88, 21-30, 2018 | 49 | 2018 |
| SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with … JC Soria, A Fülöp, C Maciel, JR Fischer, G Girotto, S Lago, E Smit, ... Annals of Oncology 28 (12), 3028-3036, 2017 | 31 | 2017 |
| Impact of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer on health-related quality of life in KEYNOTE-181 A Adenis, AS Kulkarni, GC Girotto, C de la Fouchardiere, H Senellart, ... Journal of Clinical Oncology 40 (4), 382-391, 2022 | 26 | 2022 |
| Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group RP Riechelmann, RF Weschenfelder, FP Costa, AC Andrade, AB Osvaldt, ... Ecancermedicalscience 11, 2017 | 26 | 2017 |
| Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B Sangro, SL Chan, RK Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, ... Annals of Oncology 35 (5), 448-457, 2024 | 13 | 2024 |
| Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial GT Wolf, S Liu, E Bellile, M Sartor, L Rozek, D Thomas, A Nguyen, ... Oral oncology 111, 104928, 2020 | 12 | 2020 |
| Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR … JA Ledermann, A Lortholary, RT Penson, E Gibbs, DM Provencher, ... Journal of Clinical Oncology 35 (15_suppl), 5518-5518, 2017 | 11 | 2017 |
| Tumor response and symptom palliation from RAINBOW, a phase III trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer S Cascinu, G Bodoky, K Muro, E Van Cutsem, SC Oh, G Folprecht, ... The oncologist 26 (3), e414-e424, 2021 | 5 | 2021 |
| Concordance analysis of ALK gene fusion detection methods in patients with Non–Small-Cell Lung Cancer from Chile, Brazil, and Peru G Sepúlveda-Hermosilla, M Freire, A Blanco, J Cáceres, R Lizana, ... The Journal of Molecular Diagnostics 23 (9), 1127-1137, 2021 | 3 | 2021 |
| Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic … A Adenis, A Kulkarni, GC Girotto, C De La Fouchardiere, H Senellart, ... Journal of Clinical Oncology 37 (15_suppl), 4048-4048, 2019 | 3 | 2019 |
Andrew J. ArmstrongProfessor, Duke University在 duke.edu 的电子邮件经过验证
